UBS Initiates Buy Rating on Versigent PLC
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy VGNT?
Source: seekingalpha
- Coverage Initiation: UBS has initiated coverage on Versigent PLC (VGNT) with a Buy rating, as analyst Joseph Spak notes that the current implied trading EV/EBITDA multiple is too low compared to other auto industry suppliers, indicating potential value in the stock.
- Capital Return Commitment: Spak highlights that as long as management commits to a consistent capital return program, the stock is likely to re-rate, with approximately 50% of the current market cap expected to be returned to shareholders through buybacks or dividends over the next three years, which could serve as positive catalysts.
- Price Target Setting: UBS has assigned a price target of $43 for Versigent based on a 4.5X multiple to the 2027 EV/EBITDA estimate, reflecting an optimistic outlook on the company's future growth.
- Stock Performance: Versigent's shares rose 5.9% in Tuesday afternoon trading to $32.33, within the post-spinoff trading range of $26.34 to $34.99, indicating a positive market response to the new coverage and outlook.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VGNT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VGNT
Wall Street analysts forecast VGNT stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 32.920
Low
Averages
High
Current: 32.920
Low
Averages
High
About VGNT
Versigent PLC is a Switzerland‑based company. The Company is primarily engaged in the automotive components and electrical systems industry. The Company focuses on the design, development, manufacturing, and delivery of signal, data, and power distribution systems for vehicle applications. Their core offerings include electrical architectures as well as physical electrical distribution products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UBS Initiates Buy Rating on Versigent PLC
- Coverage Initiation: UBS has initiated coverage on Versigent PLC (VGNT) with a Buy rating, as analyst Joseph Spak notes that the current implied trading EV/EBITDA multiple is too low compared to other auto industry suppliers, indicating potential value in the stock.
- Capital Return Commitment: Spak highlights that as long as management commits to a consistent capital return program, the stock is likely to re-rate, with approximately 50% of the current market cap expected to be returned to shareholders through buybacks or dividends over the next three years, which could serve as positive catalysts.
- Price Target Setting: UBS has assigned a price target of $43 for Versigent based on a 4.5X multiple to the 2027 EV/EBITDA estimate, reflecting an optimistic outlook on the company's future growth.
- Stock Performance: Versigent's shares rose 5.9% in Tuesday afternoon trading to $32.33, within the post-spinoff trading range of $26.34 to $34.99, indicating a positive market response to the new coverage and outlook.
See More
Latest Rating Changes on Wall Street
- Infleqtion Coverage Initiation: Citigroup initiates coverage of quantum computing firm Infleqtion with a Buy/High Risk rating and a $20 price target, highlighting its uniqueness in the quantum computing sector, which may attract investor interest.
- SAP Downgrade: Piper Sandler downgrades SAP from Overweight to Neutral, citing challenges in the macroeconomic environment and anticipating lower valuation multiples as the software industry transitions from SaaS to AI.
- Positive Catalysts for Alphabet: Citigroup adds a 90-day Catalyst Watch on Alphabet, expecting upcoming product updates during events like Google Cloud Next and YouTube Brandcast to drive stock price appreciation.
- Biogen Upgrade: Piper Sandler upgrades Biogen from Neutral to Overweight, raising the price target from $177 to $214, reflecting confidence in its growth potential moving forward.
See More
US Stocks Fluctuate Slightly as Oil Prices Rise Impact Market
- Market Fluctuations: The S&P 500 Index rose by 0.08%, while the Dow Jones Industrial Average fell by 0.18%, and the Nasdaq 100 Index increased by 0.04%, indicating a cautious market response amid rising oil prices and geopolitical tensions.
- Oil Price Impact: Crude oil prices surged to a four-week high due to escalating tensions with Iran, leading to declines in airline and cruise line stocks, with Norwegian Cruise Line Holdings, Carnival, and Royal Caribbean all dropping over 3%.
- Economic Data: February's non-defense capital goods new orders rose by 0.6% month-over-month, surpassing the expected 0.5%, indicating an improvement in capital spending, although consumer credit growth fell short of expectations, potentially affecting consumer confidence.
- Fed Policy Expectations: The market is pricing in only a 3% chance of a 25 basis point rate hike at the Fed's April meeting, reflecting investor caution regarding future monetary policy, especially in light of rising oil prices that could drive inflation.
See More
US Stocks Decline as Oil Prices Surge Amid Iran Tensions
- Market Decline: The S&P 500 Index fell by 0.90%, the Dow Jones Industrial Average dropped by 0.76%, and the Nasdaq 100 Index decreased by 1.40%, reflecting investor concerns over geopolitical tensions, particularly the potential escalation of conflict between Iran and the US.
- Oil Price Surge: Crude oil prices rose over 3% to a four-week high as the market watches for Iran's response to a ceasefire deadline tonight, with failure to reach an agreement potentially leading to broader military conflict and impacting global energy supplies.
- Positive Economic Data: Despite the overall market downturn, February's non-defense capital goods new orders increased by 0.6% month-over-month, surpassing expectations of 0.5%, indicating resilience in US capital spending that could support future market stability.
- Bond Market Reaction: The 10-year Treasury note yield rose to 4.357% as rising oil prices boosted inflation expectations, while the market's diminished outlook for a Fed rate hike reflects investor caution regarding future economic policies.
See More
US Stocks Decline as Oil Prices Surge Amid Iran Tensions
- Market Decline: The S&P 500 index fell by 0.63%, the Dow Jones Industrial Average dropped by 0.66%, and the Nasdaq 100 index decreased by 0.78%, reflecting investor concerns over geopolitical tensions, particularly the escalating situation in Iran that could impact market stability.
- Surge in Oil Prices: Crude oil prices rose over 2% to a four-week high, with the market closely watching diplomatic efforts ahead of President Trump's deadline, as failure to reach a ceasefire could lead to escalated conflict and further inflationary pressures.
- Supportive Economic Data: February's non-defense capital goods new orders increased by 0.6% month-over-month, surpassing expectations of 0.5%, indicating a rebound in capital spending, although overall market sentiment remains influenced by oil prices and geopolitical factors.
- Interest Rate Expectations Shift: The market is pricing in only a 3% chance of a 25 basis point rate hike by the Fed at the April meeting, reflecting cautious investor sentiment regarding economic outlook, especially in light of rising oil prices potentially driving inflation.
See More
Versigent Limited Debuts on NYSE After Spin-Off from Aptiv
- Public Listing Milestone: Versigent Limited (VGNT) rang the opening bell at the New York Stock Exchange, marking its transition to a standalone company after spinning off from Aptiv (APTV), with projected 2025 revenues of approximately $8.8 billion, net income of $528 million, and adjusted EBITDA of $893 million, indicating a robust financial foundation.
- Market Performance Review: Despite the company's industry-leading design and engineering capabilities, its stock fell 9% on debut to $28.99, with a market cap of about $2.26 billion, reflecting investor caution regarding the new auto supplier stock, potentially due to its low exposure to Chinese OEMs.
- Analyst Rating Insights: RBC Capital Markets initiated coverage on Versigent (VGNT) with a Sector Perform rating and a price target of $28, noting that its first-class engineering capabilities position it among the top three global players in automotive wire harnessing, while cautioning about potential selling pressure from low Chinese market exposure.
- Future Growth Potential: CEO Joseph Liotine emphasized that Versigent's global manufacturing capabilities and advanced expertise will help meet customer demands for greater capability with less complexity, with expectations for margin uplift from entering non-automotive markets, showcasing long-term growth opportunities.
See More
UBS Initiates Buy Rating on Versigent PLC
- Coverage Initiation: UBS has initiated coverage on Versigent PLC (VGNT) with a Buy rating, as analyst Joseph Spak notes that the current implied trading EV/EBITDA multiple is too low compared to other auto industry suppliers, indicating potential value in the stock.
- Capital Return Commitment: Spak highlights that as long as management commits to a consistent capital return program, the stock is likely to re-rate, with approximately 50% of the current market cap expected to be returned to shareholders through buybacks or dividends over the next three years, which could serve as positive catalysts.
- Price Target Setting: UBS has assigned a price target of $43 for Versigent based on a 4.5X multiple to the 2027 EV/EBITDA estimate, reflecting an optimistic outlook on the company's future growth.
- Stock Performance: Versigent's shares rose 5.9% in Tuesday afternoon trading to $32.33, within the post-spinoff trading range of $26.34 to $34.99, indicating a positive market response to the new coverage and outlook.
See More
Latest Rating Changes on Wall Street
- Infleqtion Coverage Initiation: Citigroup initiates coverage of quantum computing firm Infleqtion with a Buy/High Risk rating and a $20 price target, highlighting its uniqueness in the quantum computing sector, which may attract investor interest.
- SAP Downgrade: Piper Sandler downgrades SAP from Overweight to Neutral, citing challenges in the macroeconomic environment and anticipating lower valuation multiples as the software industry transitions from SaaS to AI.
- Positive Catalysts for Alphabet: Citigroup adds a 90-day Catalyst Watch on Alphabet, expecting upcoming product updates during events like Google Cloud Next and YouTube Brandcast to drive stock price appreciation.
- Biogen Upgrade: Piper Sandler upgrades Biogen from Neutral to Overweight, raising the price target from $177 to $214, reflecting confidence in its growth potential moving forward.
See More
US Stocks Fluctuate Slightly as Oil Prices Rise Impact Market
- Market Fluctuations: The S&P 500 Index rose by 0.08%, while the Dow Jones Industrial Average fell by 0.18%, and the Nasdaq 100 Index increased by 0.04%, indicating a cautious market response amid rising oil prices and geopolitical tensions.
- Oil Price Impact: Crude oil prices surged to a four-week high due to escalating tensions with Iran, leading to declines in airline and cruise line stocks, with Norwegian Cruise Line Holdings, Carnival, and Royal Caribbean all dropping over 3%.
- Economic Data: February's non-defense capital goods new orders rose by 0.6% month-over-month, surpassing the expected 0.5%, indicating an improvement in capital spending, although consumer credit growth fell short of expectations, potentially affecting consumer confidence.
- Fed Policy Expectations: The market is pricing in only a 3% chance of a 25 basis point rate hike at the Fed's April meeting, reflecting investor caution regarding future monetary policy, especially in light of rising oil prices that could drive inflation.
See More
US Stocks Decline as Oil Prices Surge Amid Iran Tensions
- Market Decline: The S&P 500 Index fell by 0.90%, the Dow Jones Industrial Average dropped by 0.76%, and the Nasdaq 100 Index decreased by 1.40%, reflecting investor concerns over geopolitical tensions, particularly the potential escalation of conflict between Iran and the US.
- Oil Price Surge: Crude oil prices rose over 3% to a four-week high as the market watches for Iran's response to a ceasefire deadline tonight, with failure to reach an agreement potentially leading to broader military conflict and impacting global energy supplies.
- Positive Economic Data: Despite the overall market downturn, February's non-defense capital goods new orders increased by 0.6% month-over-month, surpassing expectations of 0.5%, indicating resilience in US capital spending that could support future market stability.
- Bond Market Reaction: The 10-year Treasury note yield rose to 4.357% as rising oil prices boosted inflation expectations, while the market's diminished outlook for a Fed rate hike reflects investor caution regarding future economic policies.
See More
US Stocks Decline as Oil Prices Surge Amid Iran Tensions
- Market Decline: The S&P 500 index fell by 0.63%, the Dow Jones Industrial Average dropped by 0.66%, and the Nasdaq 100 index decreased by 0.78%, reflecting investor concerns over geopolitical tensions, particularly the escalating situation in Iran that could impact market stability.
- Surge in Oil Prices: Crude oil prices rose over 2% to a four-week high, with the market closely watching diplomatic efforts ahead of President Trump's deadline, as failure to reach a ceasefire could lead to escalated conflict and further inflationary pressures.
- Supportive Economic Data: February's non-defense capital goods new orders increased by 0.6% month-over-month, surpassing expectations of 0.5%, indicating a rebound in capital spending, although overall market sentiment remains influenced by oil prices and geopolitical factors.
- Interest Rate Expectations Shift: The market is pricing in only a 3% chance of a 25 basis point rate hike by the Fed at the April meeting, reflecting cautious investor sentiment regarding economic outlook, especially in light of rising oil prices potentially driving inflation.
See More
Versigent Limited Debuts on NYSE After Spin-Off from Aptiv
- Public Listing Milestone: Versigent Limited (VGNT) rang the opening bell at the New York Stock Exchange, marking its transition to a standalone company after spinning off from Aptiv (APTV), with projected 2025 revenues of approximately $8.8 billion, net income of $528 million, and adjusted EBITDA of $893 million, indicating a robust financial foundation.
- Market Performance Review: Despite the company's industry-leading design and engineering capabilities, its stock fell 9% on debut to $28.99, with a market cap of about $2.26 billion, reflecting investor caution regarding the new auto supplier stock, potentially due to its low exposure to Chinese OEMs.
- Analyst Rating Insights: RBC Capital Markets initiated coverage on Versigent (VGNT) with a Sector Perform rating and a price target of $28, noting that its first-class engineering capabilities position it among the top three global players in automotive wire harnessing, while cautioning about potential selling pressure from low Chinese market exposure.
- Future Growth Potential: CEO Joseph Liotine emphasized that Versigent's global manufacturing capabilities and advanced expertise will help meet customer demands for greater capability with less complexity, with expectations for margin uplift from entering non-automotive markets, showcasing long-term growth opportunities.
See More
